|Videos|October 7, 2020
Using the New Indication for Esketamine to Treat Patients with Major Depressive Disorder
Author(s)Gerard Sanacora, MD, PhD
Dr Sanacora discusses the new indication for esketamine, SPRAVATO®, and how it might be used to treat patients with Major Depressive Disorder with acute risk of suicide ideation.
Advertisement
Dr Sanacora is a Professor of Psychiatry at Yale University, Director of the Yale Depression Research Program, and Co-Director of the Yale New Haven Hospital Interventional Psychiatry Service.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Approves First At-Home Brain Stimulation Device for Treatment of Depression
2
Trontinemab Shows Promise for Treatment of Alzheimer Disease in New Data at CTAD
3
An Update on the Role of Valproate in Bipolar Disorder
4
Colors of the Year for 2026: Which Color Would You Choose for Its Psychological Benefits?
5
